Lovexair and the COPD Patients Association (APEPOC) join forces to accompany the most vulnerable groups against COVID19.
People affected by chronic, acquired or rare respiratory diseases are one of the main risk groups for COVID-19. Lovexair and APEPOC Foundation They join forces to provide the support and accompaniment services that this group currently needs.
La COPD (Chronic Obstructive Pulmonary Disease) It is the fourth cause of death in Spain, with more than 3 million people affected and an underdiagnosis of almost 80%. Today, COPD is a serious public health problem. In general, the co-morbidity and mortality associated with this pathology is unknown, but it is known that dalpha 1 antitrypsin deficiency (DAAT) is a genetic condition associated with COPD.
Patients with COPD suffer a significant decrease in their quality of life, which has repercussions at work and social levels, and they are a group that is particularly vulnerable to COVID-19, due to several factors:
- The lack of knowledge of these patients regarding preventive measures and care against possible infections or complications.
- Misinformation or unreliable advice on how to handle the situation from home, making it almost prohibitive to go to health centers during this period of time with overload.
- The saturation of consultations (in person/telephone) in clinical services to resolve recurring doubts about treatment and care or appointments that cannot be guaranteed.
A shared mission
lovexair and COPD Patients Association (APEPOC) share a mission: to provide resources that improve the quality of life of these patients, the prevention and treatment of respiratory diseases. Both with different projects underway join forces to provide better care to this group of patients, offering services and support in a coordinated manner.
The Association of COPD Patients (APEPOC) is carrying out the project #Covid19andCOPD, collecting testimonies and experiences of confinement experienced by patients and their environment.
The collaboration between the two companies allows for the free registration of a number of COPD patients in the national territory to the #Pioneers program, during this difficult period for chronic respiratory patients.
En lovexair the online project has been developed #Pioneers HappyAir, a support program and care plan for patients with COPD.
Each patient will have a coach, a respiratory physiotherapist trained in online health by the Foundation lovexair, for 6 months and will receive support throughout this period to learn to manage their symptoms, maintain consistency in their care plan and follow an active lifestyle from home and will be accompanied by video conference, through the phone or tablet when they need support.
#Pioneers HappyAir has the social endorsement of the Scientific Society of Pulmonology and Thoracic Surgery (SEPARATE) and the Respiratory Group in Primary Care (GRAP), with a clinical supervisory team that will guide this project.
From lovexair The resources of the organization are made available to those who need them. HappyAir CommunityOn the one hand, the coaches of the HappyAir Community Answer questions about respiratory diseases and COVID-19 On the line AWARENESS and on the other hand, they offer to monitor the care of any patient who requires it, regardless of their respiratory pathology.
To provide these human resources to all those who need them, the Lovexair Foundation calls for alliances and the creation of a support network through membership, donations and even sponsorships, which will allow us to provide support to as many patients as possible during confinement, de-escalation, rehabilitation due to COVID-19 and the following months.
Last updated on 3 June, 2020
[…] our respiratory physiotherapy team will answer all your questions about COVID19 and chronic respiratory diseases such as COPD, Alpha1, Asthma, etc. We want to offer information based on scientific evidence so that no one […]